文献速递浆细胞疾病

替代启动子驱动的基因表达改善多发性骨髓瘤预后分层

Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma.
PubMed 文献 · Leukemia · 2021-05-10

研究利用RNA-seq在6种B细胞亚群及32例多发性骨髓瘤(MM)患者样本中鉴定活跃启动子和替代活跃启动子,并在CoMMpass数据集595例MM患者中分析其与生存的关系。发现某些替代启动子驱动的表达与更短的无进展生存和总生存相关,且独立于遗传学改变,提示其可作为新的预后分层转录组特征。

要点

  • 替代启动子活性具有B细胞亚群和MM浆细胞特异性。
  • 部分替代启动子表达与MM患者不良生存相关且独立于遗传学异常。
  • 替代启动子可作为MM预后分层的新转录组特征。

核心结论

  • 肿瘤特异性替代活跃启动子可提供MM预后分层的新途径。

研究设计与样本

  • 利用RNA-seq数据在6种B细胞亚群(含骨髓浆细胞)和32例MM患者样本中鉴定活跃及替代活跃启动子。
  • 在CoMMpass数据集595例MM患者中分析替代启动子表达与生存的关系。

主要发现

  • 常规和替代启动子起始的表达具有B细胞亚群或MM浆细胞特异性,并与染色质为基础的启动子定义高度一致。
  • 某些替代启动子驱动的表达与MM患者更短的无进展生存和总生存相关,且独立于遗传学改变。

临床怎么用

  • 可考虑将替代启动子表达作为MM预后分层的补充转录组指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical and genetic risk factors are currently used in multiple myeloma (MM) to stratify patients and to design specific therapies. However, these systems do not capture the heterogeneity of the disease supporting the development of new prognostic factors. In this study, we identified active promoters and alternative active promoters in 6 different B cell subpopulations, including bone-marrow plasma cells, and 32 MM patient samples, using RNA-seq data. We find that expression initiated at both regular and alternative promoters was specific of each B cell subpopulation or MM plasma cells, showing a remarkable level of consistency with chromatin-based promoter definition. Interestingly, using 595 MM patient samples from the CoMMpass dataset, we observed that the expression derived from some alternative promoters was associated with lower progression-free and overall survival in MM patients independently of genetic alterations. Altogether, our results define cancer-specific alternative active promoters as new transcriptomic features that can provide a new avenue for prognostic stratification possibilities in patients with MM.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Valcárcel LV, Amundarain A, Kulis M, et al. Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. Leukemia. 2021. PMID: 33972667. doi:10.1038/s41375-021-01263-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。